For laboratory research use only.
PT-141 (bremelanotide) is a melanocortin receptor agonist peptide related to the Melanotan II chemistry lineage but developed and discussed as its own entity. Research-catalog materials and regulated pharmaceutical products that share a common name lineage still need separate frames.
Chemistry and identity
Bremelanotide is a cyclic melanocortin agonist. Analytical characterization work has mapped the acetate salt and degradation products by high-resolution LC–MS/MS, which is useful whenever lot identity and impurity profiles matter (bremelanotide acetate characterization). Medicinal-chemistry papers exploring melanocortin macrocycles often use Melanotan-II–related starting points while designing selectivity across human melanocortin receptors (melanocortin macrocycle design).
How it differs from Melanotan II
Shared ancestry is not identity. PT-141/bremelanotide receptor-profile discussions in the literature are not interchangeable with every Melanotan II paper. KPV and Melanotan I are additional neighbors that should keep their own labels.
Pharmaceutical versus research framing
Bremelanotide has regulated pharmaceutical history in some jurisdictions for specific indications. Emerging clinical-management reviews may mention melanocortin agonists among options in sexual-symptom contexts (emerging management approaches review). Those discussions attach to regulated products and clinical practice—not to unsupervised research-catalog use. Keep the frames in separate paragraphs.
Limits
Receptor claims should cite subtype-resolved primary papers when selectivity is central to interpretation.
Sources
- Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling. (Anal Methods, 2026, PMID 42485063)
- Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors. (J Med Chem, 2026, PMID 42340853)
- Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies. (Expert Rev Clin Pharmacol, 2025, PMID 41088800)